Editorial: Tofacitinib and Biologics for Moderate-To-Severe Ulcerative Colitis-What Is Best in Class? Authors’ Reply
Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.14486
Full Text
Open PDFAbstract
Available in full text
Date
January 17, 2018
Authors
Publisher
Wiley